Lilly’s Kisunla highlights growing benefit in early symptomatic Alzheimer’s disease

Eli Lilly has recently announced their new results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer’s Disease Neuroimaging Initiative.

“The TRAILBLAZER-ALZ 2 long-term extension reaffirms that Kisunla delivered sustained clinical benefit that continued to increase over three years and a consistent safety profile,” said Mark Mintun, M.D., group vice president, Neuroscience Research & Development, Eli Lilly and Company. “Participants continued to show meaningful outcomes, reinforcing the long-term value of early intervention.”

Note that the TRAILBLAZER-ALZ 2 LTE study was a Phase 3 double-blind extension of the original TRAILBLAZER-ALZ 2 trial, evaluating the efficacy and safety of Kisunla in individuals with early symptomatic Alzheimer’s disease.

In addition, Amyloid-related imaging abnormalities with edema/effusion and with hemorrhage/with hemosiderin deposition are side effects within the class of amyloid targeting therapies that do not usually cause any symptoms, but serious and life-threatening symptoms can occur. ARIA can be fatal. Carriers of one or two copies of the apolipoprotein E ε4  gene may be at higher risk of developing Alzheimer’s disease and experiencing ARIA.

---

---

Related Topics and Keywords

Alzheimer's disease, kisunla, Lilly's Kisunla